{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"101.659","value":"52.59"},{"groupId":"OG001","spread":"78.049","value":"51.49"}]}],"title":"Baseline (n:198, 195)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.809","value":"38.43"},{"groupId":"OG001","spread":"72.938","value":"58.33"}]}],"title":"Cycle 2 Day 1 (n: 185, 184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.064","value":"51.97"},{"groupId":"OG001","spread":"72.495","value":"59.08"}]}],"title":"Cycle 3 Day 1 (n: 185, 174)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.139","value":"51.28"},{"groupId":"OG001","spread":"75.350","value":"54.58"}]}],"title":"Cycle 4 Day 1 (n: 171, 159)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set (FAS) consists of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1","title":"Plasma Angiogenesis Marker: Basic Fibroblast Growth Factor (bFGF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}